Introduction
============

Peripheral arterial disease (PAD) affects nearly 202 million individuals worldwide [@B1]. It is characterized by reduced blood flow to the limbs, leading to pain, non-healing ulcers, or even limb amputation in severe cases [@B2], [@B3]. Treating severe PAD generally involves surgical revascularization [@B2], [@B3], but many patients suffering from PAD have comorbidities that prevent them from undergoing surgery. Therapeutic angiogenesis, an alternative treatment option for PAD, relies on the delivery of drugs or cells to promote blood vessel repair. Compared to conventional drug-based therapy, cell-based therapeutics may offer additional advantages given their ability to secrete paracrine signals and to respond dynamically to environmental stimuli at disease sites [@B4]. Stem cells are particularly attractive options for treating PAD, either by differentiating into cell types that make new blood vessels or indirectly by secreting paracrine signals to promote blood-vessel growth *in situ* [@B4]. However, transplanting stem cells alone has met with variable clinical success, and is often limited by poor cell engraftment and insufficient paracrine signaling.

Gene therapy has the potential to overcome these issues by overexpressing desirable therapeutic factors to promote angiogenesis. Upregulation of vascular endothelial growth factor (*VEGF*) has been shown to improve therapeutic angiogenesis achieved by endothelial progenitor cells [@B5] or adipose-derived stem cells (ADSCs) [@B6]. One limitation of previous strategies is the need for viral vectors to achieve efficient gene delivery; these vectors are associated with potential safety concerns for clinical translation [@B7]. Polymer-mediated gene delivery offers a potentially safer alternative, and has been shown to be effective in overexpressing VEGF in bone marrow-derived mesenchymal stem cells (BM-MSCs). Direct injection of VEGF-overexpressing MSC improved angiogenesis in a murine model of hindlimb ischemia, with up to 50% limb salvage [@B8]. However, VEGF exposure can yield leaky vasculature and promote exuberant inflammation [@B9], which may underlie incomplete tissue salvage. Further, patients with PAD often have comorbidities such as obesity and diabetes, and obtaining sufficient numbers of BM-MSCs is challenging [@B10]. Thus, there remains a strong need to identify alternative therapeutic gene targets and an alternative autologous cell population that is abundantly available from PAD patients, which promotes optimal therapeutic angiogenesis and tissue regeneration.

C-X-C chemokine receptor 4 (CXCR4) is a G protein-coupled receptor known to be involved in cell homing toward ischemia [@B11]. CXCR4 is expressed on progenitor and inflammatory cells, facilitating their migration toward ischemic tissues to participate in revascularization and tissue repair [@B12]. The ligand for CXCR4 is stromal cell-derived factor 1α, which is upregulated in hypoxic tissues and is secreted under the control of the transcription factor hypoxia-inducible factor 1α [@B11]-[@B13]. Due to its involvement in hypoxia signaling, the overexpression of CXCR4 by stem cells may enhance stem cell migration to tissues affected by ischemia *in vivo*. Notably, most prior approaches have focused on upregulating single growth factors, whereas overexpression of a cellular receptor such as CXCR4 may sensitize the stem cell to the environment and cause it to respond appropriately.

Compared to BM-MSCs, ADSCs are a much more abundant autologous cell source with similar phenotypes to BM-MSCs [@B14]. Clinically, ADSCs can be isolated in a minimally invasive manner using liposuction, with higher yields than can be achieved with BM-MSCs. ADSCs have been shown to promote therapeutic angiogenesis and tissue repair in animal models of hindlimb ischemia [@B15] and myocardial ischemia [@B16], possibly by secreting pro-angiogenic and anti-apoptotic cytokines [@B17]. Previously, we reported a polymer-mediated gene delivery method for overexpressing VEGF in ADSCs using poly(β-amino ester) (PBAE) nanoparticles, and demonstrated that paracrine release from these cells enhanced proliferation and tube formation by endothelial cells cultured *in vitro* [@B18].

In the present study, we sought to assess the efficacy of overexpressing CXCR4 in ADSCs for therapeutic angiogenesis and tissue regeneration using a murine model of PAD (Fig. [1](#F1){ref-type="fig"}A). We hypothesized that CXCR4 overexpression would promote ADSC survival and engraftment to the ischemic tissue *in vivo,*and that co-expression of CXCR4 and VEGF would further enhance angiogenesis. We first developed CXCR4- and/or VEGF-overexpressing ADSCs using PBAE nanoparticles, then assessed therapeutic efficacy *in vivo* by monitoring cell survival, blood reperfusion and limb salvage over time, tissue histology in the regenerated limb tissue, and the*in vivo* angiogenic and inflammatory response. Finally, the effects of CXCR4 overexpression on the paracrine signaling of ADSCs were characterized *in vitro* to help unravel the mechanisms underlying the observed tissue regeneration.

Results
=======

Polymeric nanoparticles led to efficient CXCR4 and VEGF overexpression in ADSCs
-------------------------------------------------------------------------------

To generate CXCR4- and/or VEGF-overexpressing ADSCs, poly(β-amino ester) (PBAE)-based nanoparticles containing plasmid DNA for these respective genes were applied to ADSCs *ex vivo* (Fig. [1](#F1){ref-type="fig"}A). Overexpression was verified at the mRNA level with the quantitative reverse transcription polymerase chain reaction (qRT-PCR) and at the protein level with the enzyme-linked immunosorbent assay (ELISA), western blotting, and fluorescence-activated cell sorting (FACS). The transfection efficiency achieved using PBAE nanoparticles in mouse ADSCs was assessed using wild-type mouse ADSCs with the reporter gene enhanced green fluorescent protein (GFP), which demonstrated that PBAE nanoparticles significantly improved transfection efficiency (19.9±2.0%) compared to controls (5.4±0.8%; p\<0.05; Fig. [S1](#SM1){ref-type="supplementary-material"}A-S1B) with minimal effects on ADSC viability (Fig. [S1](#SM1){ref-type="supplementary-material"}C). For all remaining experiments, transfections were carried out with GFP-positive/luciferase-positive (GFP(+)/Luc(+)) mouse ADSCs; these cells enabled live cell tracking during animal experiments.

Successful CXCR4 overexpression in ADSCs transfected using PBAE nanoparticles was confirmed with qRT-PCR (Fig. [1](#F1){ref-type="fig"}B) and western blotting (Fig. [1](#F1){ref-type="fig"}C). Quantification of CXCR4 mRNA levels over 10 days revealed that *hCXCR4* expression peaked at 48 h post-transfection and remained high over 8 days (Fig. [1](#F1){ref-type="fig"}D). To assess the level of cell-surface expression of the transmembrane receptor CXCR4, FACS was performed; surface expression was significantly greater in CXCR4-transfected cells than in GFP-transfected controls (1.41±0.02% vs. 0.9±0.11%, respectively; p\<0.05; Fig. [S2](#SM1){ref-type="supplementary-material"}). This subtle but significant effect suggests that CXCR4 protein is located predominantly within the cell, as reported previously [@B19].

VEGF overexpression was similarly confirmed through qRT-PCR (Fig. [1](#F1){ref-type="fig"}E) and ELISA (Fig. [1](#F1){ref-type="fig"}F). As with CXCR4, VEGF release peaked at 48 h and was significantly higher in VEGF-transfected ADSCs (2.41±0.19 ng/mL) and in CXCR4/VEGF-cotransfected ADSCs (0.69±0.09 ng/mL) than in GFP-transfected controls (0.25±0.4 ng/mL; p\<0.05, one-way analysis of variance; Fig. [1](#F1){ref-type="fig"}F). VEGF release from VEGF-overexpressing ADSCs remained significantly elevated over the first 6 days (p\<0.05; Fig. [1](#F1){ref-type="fig"}G).

CXCR4 overexpression enhanced ADSC engraftment and prolonged cell survival in ischemic limb muscles
---------------------------------------------------------------------------------------------------

To assess the effects of CXCR4 overexpression on ADSC survival *in vivo*, GFP(+)/Luc(+) ADSCs were injected into the medial muscles of a murine model of hindlimb ischemia (Fig. [2](#F2){ref-type="fig"}A-2D). GFP-transfected ADSCs were used as a control for PBAE-mediated transfection. Genetic upregulation of the human genes encoding *hCXCR4* and/or *hVEGF* in transplanted ADSCs was initially confirmed by harvesting ischemic tissues on day 4 and subjecting them to qRT-PCR (Fig. [2](#F2){ref-type="fig"}E). This verification further confirmed that transplanted ADSCs survived *in vivo* at least through day 4. Bioluminescence imaging (BLI) was performed to assess ADSC survival over time (Fig [2](#F2){ref-type="fig"}A-2D). The engraftment of CXCR4-, VEGF-, and CXCR4/VEGF-overexpressing ADSCs was significantly greater than that of GFP-transfected controls (13.00±6% combined for the CXCR4-, VEGF-, and CXCR4/VEGF-transfected groups vs. 6.11±3% for the GFP-transfected group at 24 h; p\<0.05; Fig. [2](#F2){ref-type="fig"}F). For all groups, BLI signal peaked at day 4 (Fig. [2](#F2){ref-type="fig"}H), indicating that the transplanted cells recovered and proliferated. At day 7, BLI signal for all groups began to decline, but the signal in the CXCR4- and CXCR4/VEGF-transfected groups remained relatively high (11.20±8.8% combined for the CXCR4- and CXCR4/VEGF-overexpressing groups) compared to the GFP-transfected groups (2.96±2.6%; p\<0.05; Fig. [2](#F2){ref-type="fig"}G). By day 10, BLI signal was only detected in the CXCR4- and CXCR4/VEGF-overexpressing groups (Fig. [2](#F2){ref-type="fig"}H), demonstrating improved cell survival due to CXCR4-overexpression.

CXCR4-overexpressing ADSCs led to faster blood reperfusion and 100% limb salvage *in vivo*
------------------------------------------------------------------------------------------

Therapeutic efficacy was evaluated by monitoring functional blood reperfusion and limb outcome. To monitor functional blood reperfusion, laser Doppler perfusion imaging was performed weekly (Fig. [3](#F3){ref-type="fig"}A-3D, Fig. [S3](#SM1){ref-type="supplementary-material"}) beginning on the day of surgery to confirm the induction of hindlimb ischemia (Fig. [3](#F3){ref-type="fig"}A-3D). By day 7, CXCR4-overexpressing groups displayed faster blood reperfusion than VEGF- and GFP-transfected groups (p\<0.05 compared to GFP; Fig. [3](#F3){ref-type="fig"}F). Relative reperfusion levels after 14 days did not significantly differ from each other (Fig. [S3](#SM1){ref-type="supplementary-material"}), indicating that the host regenerative response likely dominated the effects of the transplanted cells beyond this time point. Consequently, the faster blood reperfusion response exhibited by CXCR4 overexpression was associated with improved limb salvage.

Importantly, CXCR4 overexpression led to 100% limb salvage in all tested animals (n=8), which was the best therapeutic response in all groups (Fig. [3](#F3){ref-type="fig"}E, 3G). Co-overexpression with CXCR4/VEGF also improved limb salvage compared to the VEGF- and GFP-overexpressing groups (Fig. [3](#F3){ref-type="fig"}G), although two mice suffered toe necrosis and one mouse suffered foot necrosis. VEGF overexpression led to 50% limb salvage (Fig. [3](#F3){ref-type="fig"}G), which was greater than the limb salvage exhibited by mice transfected with GFP-control constructs, but VEGF overexpression also led to the highest amount of limb loss (Fig. [3](#F3){ref-type="fig"}G).

Muscle regeneration improved in ischemic hindlimbs with CXCR4-overexpressing ADSCs
----------------------------------------------------------------------------------

Muscle histology was performed to determine the health of ischemic limbs at 4 weeks after ischemia induction and cell transplantation (Fig. [4](#F4){ref-type="fig"}A). Sections were stained with Masson\'s trichrome and assessed for muscle regeneration or damage, which manifested as fibrosis. Regenerating muscle fibers were observed in the CXCR4- and CXCR4/VEGF-transfected groups, as indicated by the presence of centrally located nuclei (Fig. [4](#F4){ref-type="fig"}A). This observation suggested that these tissues had reached the late stage of muscle regeneration. In contrast, few regenerating muscle fibers were noted in the VEGF-transfected group; instead, classic fibrosis was observed throughout, as manifested by the increased collagen (stained blue) between muscle fibers (Fig. [4](#F4){ref-type="fig"}A). Similarly, much fibrosis was observed in the GFP-transfected group (Fig. [4](#F4){ref-type="fig"}A).

VEGF overexpression, but not CXCR4 overexpression, enhanced vessel density and inflammation *in vivo*
-----------------------------------------------------------------------------------------------------

Given that angiogenesis and inflammation are important processes in muscle repair, we immunostained ischemic tissue sections for capillaries (anti-CD31) and macrophages (anti-CD68). Transplanted cells were immunostained with anti-GFP to determine their presence and distribution (Fig. [4](#F4){ref-type="fig"}B). By 4 weeks after transplantation, most regenerated nascent capillaries arose from endogeneous cells (Fig. [4](#F4){ref-type="fig"}B). Very few transplanted cells remained; those that did remain were located in close proximity to newly formed capillaries (Fig. [4](#F4){ref-type="fig"}B). These results suggest that transplanted cells likely contribute to new blood-vessel formation mostly via paracrine signaling rather than via direct differentiation and incorporation. To gauge the magnitude of the angiogenic response, capillaries were quantified at 4 weeks. VEGF-overexpressing ADSCs displayed the largest increase in vessel density (48.9±10 vessels per high-powered field) over GFP-transfected controls (42.7±2 vessels per high-powered field; p\<0.05; Fig. [4](#F4){ref-type="fig"}D). Co-transfection with CXCR4 and VEGF also yielded increased vessel density, but this effect was not significant (Fig. [4](#F4){ref-type="fig"}D). Interestingly, vessel density in the CXCR4-transfected group did not significantly differ from density in the GFP-transfected controls (Fig. [4](#F4){ref-type="fig"}D).

Acute inflammation in response to ischemic injury has been reported to peak around days 3-7 [@B20]. As such, day-4 tissue sections were stained for CD68, a marker for macrophages, the major inflammatory cell type that responds to injuries. This analysis revealed that VEGF-overexpressing ADSCs substantially increased the acute host inflammatory response in ischemic muscles, as shown by the increased percentage of CD68-positive cells in mice transplanted with VEGF-overexpressing ADSCs (Fig. [4](#F4){ref-type="fig"}C). Both VEGF- and CXCR4/VEGF-overexpressing ADSCs prompted a significant increase in the number of CD68-positive macrophages compared to GFP-transfected controls (p\<0.05; Fig. [4](#F4){ref-type="fig"}E). In contrast, CXCR4-overexpressing ADSCs did not significantly change the number of CD68-positive cells compared to GFP-transfected controls (Fig. [4](#F4){ref-type="fig"}E).

To complement our immunostaining-based assessment of inflammation, qRT-PCR for genes encoding the inflammatory cytokines mIL-1β (Fig. [5](#F5){ref-type="fig"}A), mTNF-α (Fig. [5](#F5){ref-type="fig"}B), mIL-6 (Fig. [5](#F5){ref-type="fig"}C), and mIL-10 (Fig. [5](#F5){ref-type="fig"}D) was performed on day-4 harvested muscle tissues. Consistent with the trend of staining for CD68 (Fig. [4](#F4){ref-type="fig"}E), the VEGF-transfected group displayed significant increases in the expression of genes encoding the pro-inflammatory cytokines mIL-1β (p\<0.001; Fig. [5](#F5){ref-type="fig"}A) and mTNF-α (p\<0.001; Fig. [5](#F5){ref-type="fig"}B) compared to GFP-transfected controls, while co-transfection with CXCR4/VEGF led to significant increases in the expression of *mTNF-α* only (p\<0.001; Fig. [5](#F5){ref-type="fig"}B). Expression of *mIL-6* was significantly upregulated in both CXCR4-transfected and CXCR4/VEGF-transfected groups compared to VEGF-transfected and GFP-transfected groups (p\<0.001; Fig. [5](#F5){ref-type="fig"}C), indicating that CXCR4 plays a role in *mIL-6* upregulation. Expression of the gene encoding the anti-inflammatory cytokine mIL-10 (Fig. [5](#F5){ref-type="fig"}D) followed trends that were similar to *mTNF-α* (Fig. [5](#F5){ref-type="fig"}B), suggesting that this upregulation may occur in response to increases in the expression of the genes encoding pro-inflammatory cytokines.

CXCR4 overexpression modulated ADSC paracrine signaling by promoting a pro-angiogenic and anti-inflammatory phenotype in hypoxic culture
----------------------------------------------------------------------------------------------------------------------------------------

To elucidate how CXCR4 overexpression may lead to the observed robust tissue regeneration under ischemia, we cultured transfected ADSCs under hypoxia *in vitro* and assessed changes in the gene expression of angiogenesis and inflammation markers. Interestingly, compared to GFP-transfected cells and untransfected cells, ADSCs overexpressing CXCR4 were associated with the upregulation of genes encoding the mouse angiogenic factors mVEGF (p\<0.05), basic fibroblast growth factor (mFGF, p\<0.05), and hepatocyte growth factor (mHGF, p\<0.05; Fig. [6](#F6){ref-type="fig"}A). In terms of inflammatory cytokines, CXCR4 overexpression led to significant decreases in the expression of *mIL-1β* (p\<0.05) and *mIL-6* (p\<0.05) compared to GFP-transfected cells and untransfected cells (Fig. [6](#F6){ref-type="fig"}B). These trends were not detected for the CXCR4/VEGF-transfected or VEGF-transfected groups (Fig. [6](#F6){ref-type="fig"}A, 6B).

To further assess the changes in ADSC paracrine release due to CXCR4 overexpression, we applied paracrine molecules released from transfected ADSCs to human umbilical vein endothelial cells and a macrophage cell line (THP-1) *in vitro*. Both CXCR4-overexpressing ADSCs and VEGF-overexpressing ADSCs increased the proliferation of endothelial cells compared to controls (p\<0.01 and p\<0.001 for CXCR4- and VEGF-overexpressing ADSCs, respectively), which was not seen after co-transfection with CXCR4-VEGF (Fig. [6](#F6){ref-type="fig"}C). Macrophage migration was significantly enhanced by VEGF- and CXCR4/VEGF-transfected ADSCs (p\<0.05) compared to controls (p\<0.05). CXCR4-ADSCs did not lead to marked changes in macrophage migration (Fig. [6](#F6){ref-type="fig"}D). These results indicate that CXCR4 overexpression may promote a pro-angiogenic and anti-inflammatory phenotype of ADSCs in response to hypoxia (Fig. [6](#F6){ref-type="fig"}E), which may underlie a desirable therapeutic outcome.

Discussion
==========

PAD is a significant problem worldwide that continues to increase in prevalence [@B1]. Effective treatment for PAD remains lacking due to co-morbidities in most PAD patients that prohibit them from undergoing surgical revascularization. Stem cells hold promise for treating PAD via stimulating therapeutic angiogenesis, but the use of stem cells alone remains inconsistently efficacious, likely due to poor cell engraftment and insufficient paracrine signaling [@B21]. Genetic engineering can improve stem cell therapy by enhancing cellular processes related to cell survival, migration, and paracrine signaling [@B4]. One interesting molecule known to mediate these processes is CXCR4, which contributes to stem cell homing in ischemia and other injuries [@B11], [@B12]. In this study, we found that CXCR4 overexpression enhanced the engraftment and survival of ADSCs (Fig. [2](#F2){ref-type="fig"}F, 2G), which subsequently led to more rapid restoration of blood flow (Fig. [3](#F3){ref-type="fig"}F) and 100% limb salvage in a murine model of PAD (Fig. [3](#F3){ref-type="fig"}G). Since our approach relied on a readily available stem cell population and a non-viral transfection agent, it represents a potentially clinically translatable method for treating PAD.

One of the main goals for treating PAD is the prevention of ischemic tissue damage; thus, the most interesting result of our study was that CXCR4-overexpressing ADSCs led to 100% limb salvage in all animals examined (Fig. [3](#F3){ref-type="fig"}G). In comparison, VEGF-overexpressing ADSCs resulted in 50% limb salvage (Fig. [3](#F3){ref-type="fig"}G), which is comparable to previously reported results using VEGF-transfected endothelial progenitor cells [@B5]. Histology (Fig. [4](#F4){ref-type="fig"}A) further demonstrated that CXCR4 overexpression accelerated the regeneration of new muscle fibers in affected ischemic limb tissues 28 days after cell transplantation, which was not observed in the VEGF- or GFP-overexpressing groups (Fig. [4](#F4){ref-type="fig"}A). These findings demonstrate that CXCR4-overexpressing ADSCs exert a beneficial effect in promoting tissue salvage in ischemic tissues *in vivo*.

In terms of the mechanism of repair of ischemic damage, CXCR4-overexpressing ADSCs likely promote an early angiogenic response and moderate inflammation. CXCR4-overexpressing ADSCs were associated with a robust reperfusion response by day 7 (Fig. [3](#F3){ref-type="fig"}F), which aligned with the host healing response by day 14 (Fig. [S3](#SM1){ref-type="supplementary-material"}). Histological sections at day 28 revealed fewer capillaries in the CXCR4-overexpression group than in the VEGF-overexpressing group (Fig. [4](#F4){ref-type="fig"}B), which may suggest that the tissue-repair process had returned to baseline in animals treated with CXCR4-overexpressing ADSCs. This phenomenon could be due to the host\'s natural response to ischemic injury: blood supply increases above normal levels during healing, and then gradually returns to pre-ischemic levels upon complete repair [@B22]. The early inflammatory phase of healing is a necessary process that can damage tissue if present at excessive levels. We found that CXCR4-transfected ADSCs tended to moderate inflammation, while VEGF-transfected ADSCs led to an exuberant and likely damaging inflammatory response, as indicated by increases in the expression of genes encoding the inflammatory cytokines mIL-1β (Fig. [5](#F5){ref-type="fig"}A) and mTNF-α (Fig. [5](#F5){ref-type="fig"}B) and in the number of CD68-positive macrophages (Fig. [4](#F4){ref-type="fig"}E). These findings were further supported by our *in-vitro* data, in which paracrine release from CXCR4-transfected ADSCs cultured under hypoxia promoted endothelial cell proliferation (Fig. [6](#F6){ref-type="fig"}C) and decreased THP-1 macrophage migration (Fig. [6](#F6){ref-type="fig"}D). Differences were evident in the inflammatory cytokine profile of IL-6 between mouse whole tissue (Fig. [5](#F5){ref-type="fig"}C) and transplanted cells (Fig. [6](#F6){ref-type="fig"}B), which likely reflects differences in the host response versus the phenotypic response of the cells.

Cell engraftment and survival after transplantation remain major challenges for stem cell-based therapeutics. Our study suggests that CXCR4 overexpression may improve both of these processes. Here, CXCR4-overexpressing ADSCs, including CXCR4- and CXCR4/VEGF-transfected ADSCs, exhibited high BLI signal compared to controls at 24 h, a trend that persisted over 14 days (Fig. [2](#F2){ref-type="fig"}B). CXCR4 is a G protein-coupled receptor known to activate multiple intracellular signaling cascades that lead to cell migration and cell survival [@B23]; thus, our findings suggest a strategy for utilizing CXCR4 to overcome issues related to cell engraftment and survival. The improvements in cell engraftment and survival observed here likely contributed to the early angiogenic response achieved by CXCR4-overexpressing ADSCs, which then promoted tissue salvage.

To examine transfection efficiency, we characterized the overexpression of CXCR4 and VEGF via mRNA expression and protein secretion (Fig. [1](#F1){ref-type="fig"}B-1H). Gene expression represents a single time point (48 h), while protein secretion represents accumulated protein production over 48 h. The total amount of released protein is the more relevant quantity, as it is directly related to the amount of available paracrine signals *in vivo*. For CXCR4 overexpression, FACS revealed that cell-surface expression remained comparable to controls (Fig. [1](#F1){ref-type="fig"}D). Prior studies of CXCR4 expression in MSCs also found low cell-surface expression, and instead discovered high intracellular levels of CXCR4 [@B24]. Further studies found that intracellular CXCR4 could be rapidly induced to the cell surface by a cytokine cocktail [@B25], suggesting that the timing of CXCR4 response could be improved by increasing intracellular levels of the protein. Similarly, CXCR4 overexpression in ADSCs likely remained intracellular in the present study, as suggested by qRT-PCR, western blotting, and FACS. Considering the results from prior studies, we propose that overexpression of the gene encoding CXCR4 in ADSCs may enable enhanced receptor turnover; the continued expression of CXCR4 may prolong the cell\'s response to high SDF-1α levels.

For successful clinical translation of stem cell- and gene delivery-based therapies, there are several important bottlenecks to overcome, including (1) the need for a readily available and abundant autologous cell source, (2) the need for an efficient non-viral method for gene delivery, and (3) identification of gene targets for therapeutic efficacy. This study has shown promising results for overcoming these bottlenecks by using ADSCs [@B15], [@B17], [@B26], [@B27], by employing polymeric nanoparticles to achieve efficient gene delivery, and by identifying CXCR4 as a novel gene target to enhance stem cell survival and to accelerate angiogenesis. First, we chose ADSCs given their ease of isolation, their abundance as an autologous cell source, and their demonstrated benefit for angiogenesis *in vivo* [@B15], [@B17], [@B26], [@B27]. Second, we selected PBAE-based gene delivery because it is potentially safer than viral vectors, circumventing risks such as immunogenicity and insertional mutagenesis [@B7], [@B28]. Using high-throughput screening of polymeric vectors, we previously identified optimal polymeric vectors with high transfection efficiency [@B29], [@B30] for various human stem cells that are known to be difficult to transfect [@B31]. Unlike viral vectors, polymeric vectors transiently upregulate gene expression; the DNA does not integrate into the host genome [@B32], decreasing potential risks in humans. Third, we identified CXCR4 as a promising therapeutic gene for enhancing stem cell survival, accelerating blood reperfusion, and maximizing limb salvage. Together, the findings of this study are of great significance given the large population of patients suffering from ischemic diseases and the well-documented difficulties in modifying stem cells to achieve satisfactory therapeutic outcomes.

In the present study, the transplanted cells were a heterogeneous population, with \~20% of ADSCs transfected and 80% of ADSCs remaining naive. Regardless of the gene delivery approach (viral or non-viral), transfected cells are inherently heterogeneous populations, and they are often used directly after transfection. While it is possible to use FACS to select transfected cells prior to transplantation, it is undesirable for clinical translation due to additional time and cost requirements, as well as due to the potential negative impacts on cell viability and phenotype during sorting. Further, the heterogeneity of transplanted cells may actually facilitate tissue regeneration, as it enables the combination of paracrine signals secreted by naive stem cells as well as the enhanced paracrine signals prompted by gene delivery. We showed that transplantation of a heterogeneous population of ADSCs after CXCR4 transfection led to 100% limb salvage in the mouse hindlimb ischemia model (Fig. [3](#F3){ref-type="fig"}G). Our results confirm that ADSCs transfected using PBAE/CXCR4 polymeric nanoparticles without further purification are sufficient to induce satisfactory healing, which is highly desirable for clinical translation.

In our study, we intentionally chose to use a half dose of VEGF and CXCR4 plasmids for the co-transfected group (Fig. [1](#F1){ref-type="fig"}) in order to determine the most therapeutically efficacious genes to deliver in a clinical setting, given a single total DNA dosage. To establish fair comparisons of target gene upregulation, we characterized CXCR4 (Fig. [1](#F1){ref-type="fig"}B, C, D) and VEGF (Fig [1](#F1){ref-type="fig"}E, F) expression at the level of the gene and at the level of the protein. While the DNA plasmid dosage was half in the CXCR4/VEGF co-transfected group compared to either CXCR4 or VEGF alone, it led to expression of the gene encoding CXCR4 at a level comparable to that prompted by transfection of CXCR4 alone (Fig. [1](#F1){ref-type="fig"}B-1C). The co-transfected group displayed higher expression of the gene encoding VEGF at 48 h (Fig. [1](#F1){ref-type="fig"}E), but less accumulated VEGF protein release (Fig. [1](#F1){ref-type="fig"}F). Since we have reported complete characterization data (Fig. [1](#F1){ref-type="fig"}), our functional conclusions are based upon changes illustrated in Figure [1](#F1){ref-type="fig"}. Further, the CXCR4 and VEGF signaling pathways can influence each other [@B33], as confirmed by our data (Fig. [1](#F1){ref-type="fig"}, Fig. [6](#F6){ref-type="fig"}).

We have demonstrated the promise of CXCR4-overexpressing ADSCs for treating PAD in a mouse model of hindlimb ischemia. We chose this model because it is a well-established small animal model of PAD and because it has been widely used for assessing the efficacy of novel therapies for therapeutic angiogenesis. The promising results from the present study support the feasibility of this strategy; future work should evaluate the efficacy of CXCR4-overexpressing ADSCs in a large animal model of PAD that better mimics the scale of the human condition. Further studies in large animals are warranted to uncover modifications to the present platform that may be more relevant for human therapy. One advantage of our platform is that it requires only one injection to achieve 100% limb salvage in a murine hindlimb ischemia model (Fig. [3](#F3){ref-type="fig"}G). If necessary, multiple local cell injections could be carried out, increasing the dosage of paracrine signaling required for healing larger ischemic tissues in larger animals. Further, the current platform is a multi-step process involving cell isolation, expansion, and transfection *ex vivo* prior to transplantation, which contributes to higher cost and is subject to more stringent regulatory standards (Fig. [1](#F1){ref-type="fig"}A). To further lower the barriers for clinical translation, future research may explore the possibility of a one-step approach that enables direct transfection of freshly isolated cells in the operating room followed by direct transplantation back to the patient. Alternatively, it would be interesting to explore the possibility of implanting a drug-delivery depot into ischemic tissues to directly recruit and modify endogenous progenitor cells *in situ*, which may eliminate the need for cell isolation and modification *ex vivo*.

In summary, this study demonstrates that CXCR4-overexpressing ADSCs engineered with biodegradable polymeric nanoparticles promote therapeutic angiogenesis for the treatment of PAD. CXCR4 overexpression improves cell engraftment, prolongs cell survival, and leads to complete limb salvage and tissue regeneration in a mouse model of hindlimb ischemia. The concept of modulating cell-membrane receptors to promote a therapeutically desirable phenotype of transplanted stem cells may be broadly applicable to repairing other ischemic diseases such as myocardial infarction and stroke.

Materials and Methods
=====================

Materials
---------

Monomers for synthesizing PBAEs were purchased from Sigma-Aldrich, Scientific Polymer Products, and Molecular Biosciences. Anhydrous dimethyl sulfoxide was purchased from Sigma-Aldrich. A buffer solution (pH 5.2) of 25 mM NaOAc was prepared by diluting 3 M stock solution (Sigma-Aldrich). Plasmids pEGFP-N1 and pcDNA3.1(+)-CXCR4 were purchased from Elim Biopharmaceuticals, and pVEGF165 plasmid was obtained from Aldevron.

ADSC isolation and culture
--------------------------

ADSCs were collected by harvesting inguinal fat pads from 5-6-week-old, GFP-positive/luciferase-positive (GFP(+)/Luc(+)), transgenic male mice (kindly provided by Dr. Joseph Wu, Stanford University) and Friend Virus B wild-type male mice (Charles River). All animals were handled in accordance with the Stanford University Animal Care and Use Committee Guidelines; all protocols were approved by the Stanford University Institutional Animal Care and Use Committee. After serial betadine washes, the fat pads were finely minced in cold, sterile phosphate-buffered saline and digested with 0.075% collagenase II (Sigma-Aldrich) at 37 °C for 30 min in a shaking water bath. Digestion was neutralized with Dulbecco\'s Modified Eagle Medium (Invitrogen) supplemented with 10% fetal bovine serum (Invitrogen) and 1% penicillin-streptomycin (Sigma-Aldrich). Neutralized cells were centrifuged at 4 °C and 1,000 rpm for 5 min, and floating adipocytes and media were removed before pelleted ADSCs from the stromal-vascular portion were resuspended in culture medium, passed through a 100-μm Falcon nylon cell strainer (Becton Dickinson), and plated on a 10-cm dish. Cells were incubated at 37 °C and 5% atmospheric CO~2~. Twenty-four hours after isolation, the cells were washed in phosphate-buffered saline (Invitrogen) to remove debris and nonadherent cells, and fresh medium was added to the cells. Medium was changed every 2 days, and adherent spindle-shaped cells were grown to subconfluence, passaged using standard methods of trypsinization, and propagated through passage 2.

Synthesis of PBAEs
------------------

PBAE polymers were synthesized as previously described [@B31]. Briefly, acrylate-terminated C32 polymer was prepared by mixing butanediol (C) and aminopentanol (32) monomers using a diacrylate/amine monomer molar ratio of 1.2:1 at 90 °C for 24 h. Subsequently, amine-terminated C32 polymers were generated by reacting acrylate-terminated C32 polymer with diamine monomer (122) in dimethyl sulfoxide. End-capping reactions were performed overnight at room temperature with a 1.6-fold molar excess of amine over acrylate end groups.

Transfection
------------

ADSCs were transfected using PBAE nanoparticles containing three plasmids including CXCR4, VEGF, or GFP (control) using our previously optimized conditions [@B18]. Briefly, PBAE nanoparticles were formed by mixing PBAE polymer C32-122 with plasmids at 30:1 polymer:DNA ratio with a DNA dose of 4.5 µg in 25 mM NaAc. For transfection with both CXCR4 and VEGF, the two plasmids were combined for a total dose of 4.5 µg (a half-dose of each plasmid). After 10 min of incubation, nanoparticles were added to ADSCs cultured in Dulbecco\'s Modified Eagle Medium containing 10% fetal bovine serum. After 4 h of incubation, the medium was replaced with fresh growth medium. For *in vitro* assays, ADSCs were transfected at 3.0 x 10^5^ cells per well in 6-well plates (n=3/group). For animal studies, ADSCs were transfected in T150 tissue culture flasks at 3.5 x 10^6^ cells per flask (1.0 x 10^6^ cells were used per mouse). Cells were cultured for an additional 2 h in fresh growth medium prior to use for animal experiments. Cell viability/proliferation was evaluated at 48 h post-transfection using the Cell Titer 96 Aqueous One Solution Assay (Promega), and results were normalized by absorbance value from untransfected ADSCs (n=4 per sample).

FACS for ADSC transfection efficiency and CXCR4 cell-surface expression
-----------------------------------------------------------------------

To verify transfection efficiency with PBAE nanoparticles, GFP expression by transfected wild-type ADSCs was measured 48 h after transfection via FACS on a BD FACScalibur (BD Biosciences). Dead cells were excluded from the analysis by staining with propidium iodide (Life Technologies); 10,000 live cells per sample were included in the analysis. The percentage of GFP-positive cells was quantified using Flowjo 7.6 (Tree Star, Inc.).

qRT-PCR
-------

To confirm the transfection of CXCR4 and VEGF, total RNA was harvested from ADSCs at 48 h post-transfection using the RNeasy Kit (Qiagen). cDNA was synthesized via reverse transcription with the Superscript First-Strand Synthesis System (Invitrogen) and 1 μg of total RNA. qRT-PCR was performed using Power SYBR Green PCR Master Mix (Life Technologies) following the manufacturer\'s protocol; all samples underwent 40 cycles on an Applied Biosystems 7900 Real-Time PCR System. The relative expression level of target genes was determined by the ΔΔC~T~ method [@B34]. Target gene expression was first normalized to an endogenous housekeeping gene (the gene encoding mouse glyceraldehyde 3-phosphate dehydrogenase, *mGAPDH*), followed by a second normalization to the expression level measured in untransfected control cells. Upregulation of mouse angiogenic and inflammatory genes was confirmed by isolating total RNA from ADSCs cultured under 1% O~2~ for 48 h, then synthesizing cDNA and performing qRT-PCR. Measurement of mRNA extracted from ischemic muscle was performed by digesting muscle with TRIzol Reagent (Invitrogen) and proceeding through RNA extraction, cDNA synthesis, and qRT-PCR as described above. Four replicates were assayed per sample. All primers used in this study are listed in Table [S1](#SM1){ref-type="supplementary-material"}.

Measurement of VEGF production via ELISA
----------------------------------------

VEGF secretion by mouse ADSCs was measured in conditioned medium with the Human VEGF Standard ELISA Development Kit (Peprotech) according to the manufacturer\'s protocol. VEGF production was measured on days 2, 4, 6, and 8. Cumulative VEGF release was calculated by summing the amounts of VEGF released at all previous time points. Secreted VEGF (*in vitro*) was expressed as ng of VEGF per mL of supernatant. Three replicates were assayed per sample.

Determination of CXCR4 upregulation by western blotting
-------------------------------------------------------

CXCR4 protein production was determined by western blotting. Total protein was isolated utilizing radioimmunoprecipitation assay buffer (Thermo Scientific). Proteins were separated via gel electrophoresis on NuPage Novex Bis-Tris Mini Gels (Invitrogen) at 200 V for 35 min. Separated proteins were transferred to a polyvinylidene difluoride membrane (Invitrogen) via the XCell II Blot Module (Invitrogen) at 30 V for 1 h. To assess CXCR4 expression, blotted membranes were stained for anti-human CXCR4 (product ab124824, 1:100 dilution, Abcam) utilizing a horseradish peroxidase-labeled secondary antibody (product ab6721, 1:10000 dilution, Abcam). Staining with anti-β actin (product ab8227, 1:2000 dilution, Abcam) served as a loading control. X-ray films were developed with the chemiluminescent reagent SuperSignal West Pico (Thermo Scientific). Three replicates were performed per assay.

Transplantation of stem cells into a mouse model of hindlimb ischemia
---------------------------------------------------------------------

All animal experiments were performed in accordance with the Stanford University Animal Care and Use Committee Guidelines and approved Animal Panel on Laboratory Animal Care protocols. Hindlimb ischemia was induced in female Friend Virus B mice aged 10-12 weeks (Charles River), as previously described [@B35], [@B36]. Briefly, the femoral artery was ligated at two sites (distal to the external iliac artery and proximal to the popliteal artery) through a skin incision with 5-0 silk suture (Ethicon). The femoral artery was excised between the points of ligation. After arterial dissection, cells (1.0 x 10^6^ cells per injection) were suspended in 100 µL phosphate-buffered saline and injected intramuscularly into two sites (the adductor muscle region in the medial thigh and the gastrocnemius) using 29-gauge tuberculin syringes. Four experimental groups (n=11/group) consisted of animals that received CXCR4-transfected ADSCs, CXCR4/VEGF-transfected ADSCs, VEGF-transfected ADSCs, or GFP-transfected ADSCs (control). All transfected genes were human species and all ADSCs were mouse species. Physiological status of ischemic limbs was followed up to 4 weeks after treatment. Animals were euthanized via cervical dislocation at two time points: after 4 days (n=3) and after 4 weeks (n=8). Limbs of the ischemic sides were retrieved for analysis.

BLI
---

ADSC survival was monitored after injection via BLI over 2 weeks (on the day of surgery and on days 1, 3, 4, 7, 10, and 14). Animals were anesthetized with 2-3% inhaled isoflurane and injected intraperitoneally with the reporter probe D-luciferin at 100 mg/kg body weight. The IVIS Spectrum system (Xenogen) was used to image the animals under 2% inhaled isoflurane anesthesia. Each animal was scanned until peak signal was reached. Radiance was quantified in photons/s/cm^2^/steradian.

*In-vivo* assessment of limb salvage and limb reperfusion
---------------------------------------------------------

Ischemic limbs were evaluated via direct observation of limb status and via measurement of blood reperfusion. Limbs were assessed every week up to 4 weeks. Grading of limb ischemia was based on the severity of limb ischemia as: 1) limb salvage (no observable limb injury), 2) toe necrosis, 3) foot necrosis, 4) foot loss, and 5) limb loss. Blood reperfusion in ischemic limbs was measured using a PeriScan PIM3 laser Doppler system (Perimed AB) as previously described [@B35], [@B36]. Briefly, each animal was pre-warmed to a body temperature of 36 °C. Regions of interest were drawn around entire hindlimbs, and the levels of perfusion in ischemic and normal hindlimbs were quantified using the mean pixel value within each region of interest. Relative changes in blood flow were expressed as the ratio of the ischemic limb to the normal limbs.

Histology, immunofluorescence, capillary densitometry, and macrophage quantification
------------------------------------------------------------------------------------

Mice were euthanized at 4 days and 4 weeks to retrieve muscle tissue from ischemic limbs for histology. Specimens were embedded in optimal cutting temperature (O.C.T; Tissue-Tek) compound for cryosectioning. Sections were cut at 8-µm thickness. General muscle health (regeneration and fibrosis) was assessed via staining with Masson\'s trichrome. Immunofluorescence was performed to assess features of angiogenesis and inflammation. Sections of day-28, transplanted, GFP(+)/Luc(+) cells were stained with anti-GFP (product \#A-21312, 1:200 dilution, Invitrogen). Capillaries were detected with anti-CD31 (product \#550274, 1:50 dilution, BD Pharmingen). Macrophages were detected with anti-CD68 (product \#MCA1957, 1:100 dilution, AbD Serotec). Rhodamine anti-rat antibodies (product \#31680, 1:200 dilution, Thermo Scientific) were used as secondary antibodies for both CD31 and CD68 staining. Sections were mounted with Vectashield Mounting Medium with 4\',6-diamidino-2-phenylindole (DAPI; Vector Laboratories) to counterstain nuclei. Sections were imaged with a fluorescence microscope (Axio Observer, Zeiss). The number of CD31-positive cells was quantified to estimate capillary density per high-powered field using ImageJ v1.48 (NIH). Quantitative analysis of macrophages was performed by determining the number of DAPI-positive cells that overlapped with CD68-positive signals; analysis was performed using MATLAB R2010a (MathWorks).

Statistical analysis
--------------------

GraphPad Prism 6 (Graphpad Software) was used for all statistical analyses. One-way analysis of variance with Dunnett\'s multiple comparison post-hoc test was performed to compare all experimental groups and to determine statistical significance. Comparisons between control groups and combined groups were carried out using Student\'s t-test. All quantitative data were expressed as mean ± standard error. A calculated p-value of less than 0.05 was used to reject the null hypothesis.
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![**Development of CXCR4- and/or VEGF-overexpressing mouse ADSCs using PBAE nanoparticles.** (**A**) Schematic of experimental design. Briefly, mouse ADSCs were transfected *ex vivo* with PBAE nanoparticles carrying plasmid DNA (pDNA) encoding human genes for *hCXCR4* and/or *hVEGF*. Transfected ADSCs were transplanted into murine models of hindlimb ischemia to assess their ability to promote therapeutic angiogenesis. CXCR4 overexpression in mouse ADSCs was verified with qRT-PCR (**B**) and by western blot (**C**) at 48 h post-transfection. (**D)** qRT-PCR demonstrated that *hCXCR4 mRNA* overexpression was transient, peaking at 48 h and declining over 8 days. VEGF overexpression was also verified through qRT-PCR (**E**) and ELISA (**F**) at 48 h. (**G**) Similarly, increased VEGF release was transient as demonstrated by VEGF ELISA: peak release occurred over the first 48 h and declined to basal levels by 10 days. Abbreviations: C: CXCR4; CV: CXCR4/VEGF; V: VEGF; G: GFP; rel.: relative; conc.: concentration; WT: wild-type. All data are reported as mean ± standard error, n=3. \*p\<0.05 and \*\*p\<0.01 compared with GFP-ADSC controls. ^\#^p\<0.05.](thnov06p1176g001){#F1}

![**CXCR4-overexpressing ADSCs displayed improved cell engraftment and survival in murine models of hindlimb ischemia.** (**A-D**) Representative BLI of mouse ischemic hindlimbs transplanted with GFP(+)/Luc(+) mouse ADSCs transfected with CXCR4 (**A**), CXCR4/VEGF (**B**), VEGF (**C**), or GFP (**D**) over 14 days post-ischemia induction. (**E**) Confirmation of human CXCR4 and human VEGF overexpression in transplanted ADSCs by qRT-PCR performed on harvested tissue at 4 days post-procedure (data are expressed as mRNA expression relative to single transfection with *hCXCR4* or *hVEGF*). Percentage of BLI signal remaining from transplanted cells measured 24 h (**F**) and 7 days (**G**) after cell transplantation. (**H**) Quantitative BLI signal of transplanted GFP(+)/Luc(+) ADSCs demonstrates prolonged cell survival by CXCR4-overexpressing groups over 14 days post-ischemia induction (expressed as percent of BLI signal relative to day 0 signal). Abbreviations: C: CXCR4; CV: CXCR4/VEGF; V: VEGF; G: GFP; rel.: relative; h: human. All data are reported as mean ± standard error, n=8. \*p\<0.05 compared with GFP-ADSC controls.](thnov06p1176g002){#F2}

![**Early reperfusion and enhanced therapeutic efficacy in ischemic hindlimbs**. (**A-D**) Representative laser Doppler perfusion imaging of ischemic hindlimbs transplanted with mouse ADSCs transfected with CXCR4 (**A**), CXCR4/VEGF (**B**), VEGF (**C**), or GFP (**D**) over 14 days post-ischemia induction. (**E**) Gross observation of hindlimbs at day 14 post-procedure demonstrating enhanced limb salvage by CXCR4 overexpression (red circles indicate ischemic limbs). (**F**) Quantification of blood reperfusion at day 7 demonstrating significantly enhanced early perfusion by CXCR4-overexpressing ADSCs. (**G**) Quantification of limb outcome demonstrates 100% limb salvage by CXCR4 overexpression and improved limb salvage by VEGF and CXCR4/VEGF in comparison to GFP controls. Abbreviations: C: CXCR4; CV: CXCR4/VEGF; V: VEGF; G: GFP. All data are reported as mean ± standard error, n=8. \*p\<0.05 compared with GFP-ADSC controls.](thnov06p1176g003){#F3}

![**Enhanced muscle regeneration and modulated host angiogenic and inflammatory response by CXCR4-overexpressing ADSCs.**(**A**) Representative tissue sections at 4 weeks after ischemia induction stained with Masson\'s trichrome demonstrating enhanced muscle fiber regeneration (black arrows) from CXCR4 overexpression and prolonged muscle fibrosis (yellow arrows) from VEGF and GFP overexpression (scale bar: 500 μm). (**B**) Immunostaining of tissue sections at 4 weeks after ischemia induction for capillaries (red, anti-CD31), transplanted cells (green, anti-GFP), and nuclei (blue, 4\',6-diamidino-2-phenylindole (DAPI)) (scale bar: 250 μm). VEGF overexpression, not CXCR4 overexpression, was associated with enhanced capillary density. Transplanted stem cells that remained in tissues engrafted into capillaries, as demonstrated by overlapping GFP and CD31 staining. (**C**) Immunostaining of tissue sections at 4 days after transplantation for macrophages (red, anti-CD68) and nuclei (blue, DAPI) (scale bar: 500 μm). VEGF overexpression was associated with increased macrophage infiltrate. (**D**) Quantification of CD31-positive capillaries per high-powered field (hpf) showing increased capillary density in animals with ADSCs overexpressing VEGF. (**E**) Ratio of CD68-positive macrophages demonstrating increased inflammation due to VEGF overexpression. Abbreviations: C: CXCR4; CV: CXCR4/VEGF; V: VEGF; G: GFP. All data are reported as mean ± standard error, n=4 for week 4 histological analysis and quantification and n=3 for day 4 analysis. \*p\<0.05 compared with GFP-ADSC controls.](thnov06p1176g004){#F4}

![**Inflammatory assessment of ischemic hindlimbs**. (**A-B**) qRT-PCR of tissue harvested at day 4 for the genes encoding the inflammatory cytokines mIL-1β (**A**), mTNFα (**B**), mIL-6 (**C**), and mIL-10 (**D**). Significantly increased levels of *mIL-1β* and *mTNF-α* indicate an increased inflammatory response due to VEGF overexpression, but this increase was absent from CXCR4-overexpressing and GFP-control tissues. Increased levels of *mIL-6* indicate that a more complex anti- and pro-inflammatory response may be occurring due to CXCR4 overexpression. The cytokine mIL-10 is an anti-inflammatory marker that may be elevated in response to the inflammatory response associated with VEGF overexpression. Abbreviations: C: CXCR4; CV: CXCR4/VEGF; V: VEGF; G: GFP; rel. relative. All data are reported as mean ± standard error, n=3. \*\*p\<0.01, \*\*\*p\<0.001 compared with GFP-ADSC controls.](thnov06p1176g005){#F5}

![**CXCR4-based promotion of a pro-angiogenic and anti-inflammatory phenotype in ADSCs under hypoxia.**Transfected mouse ADSCs were cultured under hypoxia *in vitro* and assessed after 48 h via qRT-PCR of genes encoding markers of angiogenesis (**A**) and inflammation (**B**) (measurements are relative to ADSCs cultured under normoxia). Hypoxia-cultured ADSCs overexpressing CXCR4 had increased expression of angiogenic genes (*mVEGF*, *mFGF*, *mHGF*) and decreased gene expression of inflammatory markers (*mIL-1* and *mIL-6*). (**C**) Enhanced proliferation of human umbilical vein endothelial cells (HUVECs) occurred *in vitro* after exposure to paracrine release from ADSCs overexpressing CXCR4. (**D**) Paracrine release from VEGF-overexpressing, but not CXCR4-overexpressing ADSCs led to increased THP-1 macrophage migration *in vitro*. (**E**) Proposed model for a CXCR4-mediated therapeutic response to tissue ischemia. SDF-1α (red) is secreted from sites of ischemia, which activates CXCR4 (blue) on the surfaces of transfected ADSCs to promote ischemia-specific responses in angiogenesis and inflammation. Abbreviations: C: CXCR4; CV: CXCR4/VEGF; V: VEGF; G: GFP; rel.: relative; m, mouse. All data are reported as mean ± standard error, n=8. \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001 compared with GFP-ADSC controls.](thnov06p1176g006){#F6}
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